Table 3.
Regression modeling results for echocardiographic measurements stratified by ventricular morphology
| Echocardiographic measurements | Single right ventricle
|
Single left ventricle or mixed ventricular morphology
|
p* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Coefficient | 95% CI | p | n | Coefficient | 95% CI | p | n | ||
| Ventricular inflow | |||||||||
| E velocity (cm/s) | 5.0 | (−2.7, 13) | 0.19 | 15 | 5.0 | (−3.8, 14) | 0.25 | 12 | 0.99 |
| A velocity (cm/s) | –1.4 | (−5.1, 2.3) | 0.45 | 14 | 3.6 | (−0.59, 7.7) | 0.09 | 11 | 0.09 |
| Tissue Doppler | |||||||||
| S′ velocity (cm/s) | 0.20 | (−0.52, 0.91) | 0.57 | 13 | 0.28 | (−0.49, 1.1) | 0.46 | 12 | 0.87 |
| E′ velocity (cm/s) | 0.41 | (−1.1, 2.0) | 0.58 | 13 | 0.45 | (−1.3, 2.2) | 0.59 | 12 | 0.97 |
| A′ velocity (cm/s) | –0.10 | (−0.91, 0.70) | 0.79 | 12 | –0.074 | (−0.95, 0.81) | 0.86 | 11 | 0.96 |
| Diastolic performance | |||||||||
| E velocity/A velocity | 0.076 | (−0.15, 0.31) | 0.49 | 14 | –0.0094 | (−0.27, 0.25) | 0.94 | 11 | 0.62 |
| E velocity/E′ velocity | 0.29 | (−1.4, 2.0) | 0.73 | 13 | 0.22 | (−1.6, 2.0) | 0.80 | 12 | 0.96 |
| Systolic performance | |||||||||
| VTI × HR (cm × bpm) | 38 | (−93, 170) | 0.56 | 15 | 220 | (62, 380) | 0.01 | 11 | 0.08 |
| VTI (cm) | 0.63 | (−1.2, 2.4) | 0.48 | 15 | 1.8 | (−0.15, 3.8) | 0.07 | 12 | 0.38 |
| Heart rate (bpm) | 1.3 | (−4.7, 7.3) | 0.66 | 15 | 2.7 | (−4.6, 10) | 0.45 | 11 | 0.76 |
| Global ventricular performance | |||||||||
| MPI | −0.043 | (−0.10, 0.016) | 0.15 | 14 | −0.057 | (−0.12, 0.0081) | 0.08 | 12 | 0.73 |
Data are presented as coefficient, 95% CI, and p value. Each regression coefficient corresponds to the difference in the average post-phase outcome between sildenafil and placebo adjusted for pre-phase values, study period, and treatment sequence
*
p-value from test of interaction evaluating whether the treatment difference is equal in the two morphology strata
n number of subjects with a complete measurement series